Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)

Summary

The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).

Timeline

Start

2022-09-15

Primary completion

2025-02-10

Completion

2025-03-31

Drugs

Indications